Urinary Melatonin in Relation to Postmenopausal Breast Cancer Risk According to Melatonin 1 Receptor Status - PubMed (original) (raw)

Urinary Melatonin in Relation to Postmenopausal Breast Cancer Risk According to Melatonin 1 Receptor Status

Elizabeth E Devore et al. Cancer Epidemiol Biomarkers Prev. 2017 Mar.

Abstract

Background: Urinary melatonin levels have been associated with a reduced risk of breast cancer in postmenopausal women, but this association might vary according to tumor melatonin 1 receptor (MT1R) expression.Methods: We conducted a nested case-control study among 1,354 postmenopausal women in the Nurses' Health Study, who were cancer free when they provided first-morning spot urine samples in 2000 to 2002; urine samples were assayed for 6-sulfatoxymelatonin (aMT6s, a major metabolite of melatonin). Five-hundred fifty-five of these women developed breast cancer before May 31, 2012, and were matched to 799 control subjects. In a subset of cases, immunohistochemistry was used to determine MT1R status of tumor tissue. We used multivariable-adjusted conditional logistic regression to estimate the relative risk (RR) of breast cancer [with 95% confidence intervals (CI)] across quartiles of creatinine-standardized urinary aMT6s level, including by MT1R subtype.Results: Higher urinary melatonin levels were suggestively associated with a lower overall risk of breast cancer (multivariable-adjusted RR = 0.78; 95% CI = 0.61-0.99, comparing quartile 4 vs. quartile 1; _P_trend = 0.08); this association was similar for invasive vs. in situ tumors (_P_heterogeneity = 0.12). There was no evidence that associations differed according to MT1R status of the tumor (e.g., _P_heterogeneity for overall breast cancer = 0.88).Conclusions: Higher urinary melatonin levels were associated with reduced breast cancer risk in this cohort of postmenopausal women, and the association was not modified by MT1R subtype.Impact: Urinary melatonin levels appear to predict the risk of breast cancer in postmenopausal women. However, future research should evaluate these associations with longer-term follow-up and among premenopausal women. Cancer Epidemiol Biomarkers Prev; 26(3); 413-9. ©2016 AACR.

©2016 American Association for Cancer Research.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: The authors declare no potential conflicts of interest.

Similar articles

Cited by

References

    1. Stevens RG, Brainard GC, Blask DE, Lockley SW, Motta ME. Breast cancer and circadian disruption from electric lighting in the modern world. CA: a cancer journal for clinicians. 2014;64:207–18. - PMC - PubMed
    1. Hardeland R, Cardinali DP, Srinivasan V, Spence DW, Brown GM, Pandi-Perumal SR. Melatonin--a pleiotropic, orchestrating regulator molecule. Progress in neurobiology. 2011;93:350–84. - PubMed
    1. Hill SM, Frasch T, Xiang S, Yuan L, Duplessis T, Mao L. Molecular mechanisms of melatonin anticancer effects. Integrative cancer therapies. 2009;8:337–46. - PubMed
    1. Proietti S, Cucina A, Reiter RJ, Bizzarri M. Molecular mechanisms of melatonin’s inhibitory actions on breast cancers. Cellular and molecular life sciences : CMLS. 2013;70:2139–57. - PMC - PubMed
    1. Schernhammer ES, Hankinson SE. Urinary melatonin levels and breast cancer risk. Journal of the National Cancer Institute. 2005;97:1084–7. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources